Local view for "http://purl.org/linkedpolitics/eu/plenary/2003-01-30-Speech-4-046"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2003-01-30"^^xsd:date2
dcterms:Is Part Of	lp_eu:Aid for poverty diseases2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20030130.2.4-046"2
lpv:hasSubsequent	lp_eu:2003-01-30-Speech-4-0472
lpv:speaker	lp:Gérard Caudron2
lpv:spokenAs	member; Committee on Industry, External Trade, Research and Energy (2002-01-17--2004-07-19)3,3 unknown; Socialiste Indépendant (2002-07-10--2004-07-19)3,3 substitute; Delegation to the EU-Bulgaria Joint Parliamentary Committee (2002-10-14--2004-07-19)3,3 member_of_the_bureau; EUL/NGL (2002-09-10--2004-07-19)3,3 member; Delegation to the EU-Poland Joint Parliamentary Committee (2002-02-06--2004-04-30)3,3 substitute; Committee on Foreign Affairs, Human Rights, Common Security and Defence Policy (2002-09-09--2004-07-19)3,3
lpv:translated text	"Mr President, ladies and gentlemen, speaking as the rapporteur concerned with the implementation, via an Article 169 programme to which EUR 600 million was allocated, of a partnership between Europe and the developing countries in the field of research to combat HIV/AIDS, malaria and tuberculosis, I should like to congratulate Mr Wijkman. We are of course all aware of the urgency and gravity of the situation. Five million people die each year of one of these three diseases. Almost 40 million people are infected by AIDS/HIV, and 90% of them live in developing countries, most of those – 70% – in sub-Saharan Africa. We are also seeing tuberculosis making a comeback. As for malaria, which reappeared in the seventies, it is once again affecting countries in which it had been eradicated. There is no need to say any more, except that the European Union owes it to itself to adopt, quickly, a strategy to combat these diseases effectively. The regulation that we are discussing here defines the framework for Community action. It also creates the legal basis for Europe’s contribution, the aim being to encourage research to develop medicines, treatments and vaccines and to facilitate access to them. This is absolutely vital, because only 10% of research activities concern diseases which are responsible for 90% of disease in the world. We therefore need to carry out public research and encourage the private sector to invest in it. We must also, above all, ensure that these medicines are suitable for the living conditions that prevail in the countries concerned, so that they can be distributed via health systems which are worthy of the name. Finally, we must ensure that the prices are not prohibitive, and here we come back to the problem of intellectual property. I support this report, Mr President, and I hope that it will be adopted at first reading."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph